"...Industry feels that regulations we have made are too difficult; ...I think, what we need to do is strike a balance...," Azad told reporters here.
Speaking on the sidelines after inaugurating Baxter Global Research Center at Syngene here, he said "...What we are hearing from the industry is that earlier the number of clinical trials which was taking place has dropped to half, more than half."
"While we are happy that the new dispensation is in the interest of the country and is in the interest of the patient on whom the trials were taking place, at the same time we should also see that new innovations should come up and whole industry should not fall short of holding clinical trial...," he said.
To a question whether any "tinkering" was going on in the government about the same, he said "no, not at the moment".
You’ve reached your limit of 10 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app

